Year: 2024

Check Point Software Reports 2024 Third Quarter Financial Results

Written by Customer Service on October 29, 2024. Posted in Earnings Releases And Operating Results.

REDWOOD CITY, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) — Check Point® Software Technologies Ltd. (NASDAQ: CHKP), today announced its financial results for the third quarter ended September 30, 2024. Third Quarter 2024:Total Revenues: $635 million, a 7 percent increase year over year Security Subscriptions Revenues: $277 million, a 12 percent increase year over year GAAP Operating Income: $218 million, representing 34 percent of revenues Non-GAAP Operating Income: $274 million, representing 43 percent of revenues GAAP EPS: $1.83, a 4 percent increase year over year Non-GAAP EPS: $2.25, a 9 percent increase year over year“Check Point delivered great third quarter financial results that were bolstered by double-digit Infinity Platform growth. This success is underscored by double-digit revenue growth in Harmony Email and Infinity...

Orion Group Interim Report January–September 2024

Written by Customer Service on October 29, 2024. Posted in Earnings Releases And Operating Results.

ORION CORPORATION INTERIM REPORT 1–9/2024 29 OCTOBER 2024 at 12:00 EET Orion Group Interim Report January–September 2024Net sales totalled EUR 1,108.0 (January–September 2023: 868.5) million Operating profit was EUR 323.8 (182.0) million Basic earnings per share were EUR 1.83 (1.01) Cash flow from operating activities per share was EUR 1.46 (0.50) The outlook for 2024 was upgraded during the reporting period on 11 September 2024: Net sales are estimated to be EUR 1,470 million to EUR 1,510 million. Operating profit is estimated to be EUR 370 million to EUR 400 million. Previously net sales were estimated to be EUR 1,440 to EUR 1,480 and operating profit was estimated to be EUR 350 million to EUR 380 million.Key figures 7–9/24 7–9/23 Change % 1–9/24 1–9/23 Change % 1–12/23Net sales, EUR million 471.3 301.1 +56.5% 1,108.0 868.5 +27.6% 1,189.7EBITDA,...

Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting

Written by Customer Service on October 29, 2024. Posted in Public Companies.

CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the company will host a conference call and webcast on Tuesday, November 5, 2024, at 8:30 a.m. ET to discuss its third quarter 2024 financial results and review the company’s abstracts accepted for presentation at the upcoming 66th Annual Meeting of the American Society for Hematology (ASH). A live webcast of the presentation will be available here and under “Events & Presentations” in the Investors section of the company’s website at www.beamtx.com. A replay of the webcast will be archived on the company’s website for 60 days following the presentation. About Beam TherapeuticsBeam Therapeutics (Nasdaq: BEAM) is a biotechnology...

First Patient Enrolled in Teleflex’s Barrigel™ Rectal Spacer Trial for Post Radical Prostatectomy Radiation Therapy (PPRT)

Written by Customer Service on October 29, 2024. Posted in Public Companies.

Randomized, controlled study will be first in personalized spacing evidence to include patients who have a prostate cancer recurrence after prostatectomy. WAYNE, Pa., Oct. 29, 2024 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the first patient enrolled in the latest Barrigel™ rectal spacer randomized, controlled, single-blinded multicenter study: The PPRT Trial. Barrigel™ rectal spacer is the first and only sculptable hyaluronic acid rectal spacer designed to significantly reduce radiation that reaches the rectum during prostate radiation therapy.1-3 This new study will evaluate Barrigel™ rectal spacer in patients undergoing hypofractionated post-prostatectomy radiation therapy across sites in the U.S. and one site in Australia. “Our...

Medigene to Present at Upcoming Investor Conferences

Written by Customer Service on October 29, 2024. Posted in Public Companies.

Planegg/Martinsried, October 29, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, will attend BIO-Europe from November 4-6, 2024 in Stockholm as well as at the Investival Showcase Biotech, Heathcare, Medtech conference on November 18, 2024 in London. In addition, the Company will present at the Deutsches Eigenkapitalforum from November 25-27, 2024 in Frankfurt. BIO-Europe 2024https://informaconnect.com/bioeurope/?_gl=1*1qoi48c*_up*MQ..&gclid=EAIaIQobChMI_7j-_9KfiQMVcwgGAB3GfjujEAAYASAAEgKWwvD_BwELocation: Stockholmsmässan- Stockholm, Sweden Date / time: November 4-6, 2024 Members of Medigene’s Corporate Development team will be available for one-on-one meetings at the...

Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting

Written by Customer Service on October 29, 2024. Posted in Public Companies.

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that data from the Phase 2a trial of batoclimab in Graves’ disease will be the subject of an oral presentation of a late-breaking abstract accepted for the 2024 American Thyroid Association (ATA) Annual Meeting being held October 30 to November 3, 2024, in Chicago, Illinois. New data highlighting both thyroid-specific and extrathyroidal manifestations of Graves’ disease will be presented. Late-Breaking Oral Presentation Details:Title: Efficacy and Safety of the FcRn Inhibitor, Batoclimab, in Graves’ Thyroidal and Extrathyroidal Disease: a Proof-of-concept StudyPresentation: #0020Session: #5 – Autoimmune Thyroid DiseaseDate...

Azimut Discovers High-Grade Antimony Zone on the Wabamisk Gold Property, James Bay Region, Quebec

Written by Customer Service on October 29, 2024. Posted in Public Companies.

3.92% Sb, 0.3 g/t Au over 14.0 m including 11.84% Sb, 1.18 g/t Au over 3.0 m (channel sampling, open in all directions) 5,000-metre maiden drilling program to start in November LONGUEUIL, Quebec, Oct. 29, 2024 (GLOBE NEWSWIRE) — Azimut Exploration Inc. (“Azimut” or the “Company”) (TSXV: AZM) (OTCQX: AZMTF) is pleased to announce the discovery of a high-grade antimony corridor (the “Fortin Zone”) on its wholly-owned Wabamisk Property (the “Property”) in the Eeyou Istchee James Bay (“James Bay”) region of Quebec. In 2022, Azimut regained a 100% interest in the Property after Newmont withdrew from its 51% interest in the joint venture project (see press releases of August 8 and September 9, 2022). Azimut staked the Property in 2003 and optioned it to Placer Dome in 2005 before the option was transferred to Goldcorp and then Newmont....

BIO-key Secures $910,000 Order to Upgrade Long-Time Financial Services Customer to Enhanced Biometric Customer Identification Technology

Written by Customer Service on October 29, 2024. Posted in Public Companies.

HOLMDEL, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) — BIO-key® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring Identity-Bound Biometrics (IBB) for phoneless, tokenless, passwordless and phish-resistant authentication, announced that it has received a $910,000 order from a long-term financial services customer to upgrade to BIO-key’s “fingerprint only” Biometric Customer Identification Technology. The technology enhancement builds on the customer’s expanding deployment of BIO-key technology to verify the identity of customers, now totaling over 25 million enrolled individuals. Previously customers were verified at a branch location by matching their fingerprint scan and their ID number, account number or card. By upgrading to BIO-key’s “fingerprint...

CECO Environmental Reports Third Quarter 2024 Results

Written by Customer Service on October 29, 2024. Posted in Earnings Releases And Operating Results.

Company Produces Record Q3 Bookings and Highest-Ever BacklogQ3 Revenue and Income Impacted by Customer-Driven Project DelaysAnnounced the Acquisition of Profire Energy (Nasdaq: PFIE) for $125 MillionCompleted Acquisition of WK, in Early OctoberUpdates FY24 Guidance and Introduces 2025 Outlook DALLAS, Oct. 29, 2024 (GLOBE NEWSWIRE) — CECO Environmental Corp. (Nasdaq: CECO) (“CECO”), (the “Company”), a leading environmentally focused, diversified industrial company whose solutions protect people, the environment, and industrial equipment, today reported its financial results for the third quarter of 2024. In addition, CECO, announces it has completed the acquisition of WK, an Industrial Air company headquartered in Germany, in early October. Additionally, the Company announced the acquisition of Profire Energy, Inc. (NASDAQ:...

Scilex Holding Company, Following its Prior Announcement of the Record Date for a Dividend of Preferred Stock, Reiterates Information Previously Provided to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock

Written by Customer Service on October 29, 2024. Posted in Public Companies.

Scilex management is determined to enhance its stockholders’ value and protect their stockholder rights, and is taking steps to combat manipulative and naked short selling practices in Scilex common stock. Scilex notified NASDAQ on October 28, 2024 that it has set a record date of November 7, 2024 for the dividend of Scilex preferred stock to Scilex’s stockholders and certain other securityholders of Scilex. Such record date may be changed by Scilex’s board of directors for any reason at any time prior to the actual payment of such dividend of Scilex preferred stock. No payment date has been set for the payment of such dividend and such payment is conditioned upon the Scilex board of directors not having revoked the dividend prior to the payment date. Of the approximately 197 million shares of Scilex common stock currently issued and...

Year: 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals